I P Everall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9075725/publications.pdf

Version: 2024-02-01

304368 276539 5,559 48 22 41 citations h-index g-index papers 48 48 48 11695 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry,the, 2020, 7, 547-560.	3.7	4,086
2	Microglial activation and progressive brain changes in schizophrenia. British Journal of Pharmacology, 2016, 173, 666-680.	2.7	185
3	Predicting the diagnosis of autism spectrum disorder using gene pathway analysis. Molecular Psychiatry, 2014, 19, 504-510.	4.1	136
4	Invited Review: The spectrum of neuropathology in COVIDâ€19. Neuropathology and Applied Neurobiology, 2021, 47, 3-16.	1.8	99
5	Evidence for Network-Based Cortical Thickness Reductions in Schizophrenia. American Journal of Psychiatry, 2019, 176, 552-563.	4.0	97
6	Brain network dynamics in schizophrenia: Reduced dynamism of the default mode network. Human Brain Mapping, 2019, 40, 2212-2228.	1.9	72
7	PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia. Translational Psychiatry, 2017, 7, e1225-e1225.	2.4	70
8	Adverse obstetric and neonatal outcomes in women with severe mental illness: To what extent can they be prevented? Schizophrenia Research, 2014, 157, 305-309.	1.1	57
9	Early origins of mental disorder - risk factors in the perinatal and infant period. BMC Psychiatry, 2016, 16, 270.	1.1	57
10	Investigation of peripheral complement factors across stages of psychosis. Schizophrenia Research, 2019, 204, 30-37.	1.1	50
11	White matter connectivity disruptions in early and chronic schizophrenia. Psychological Medicine, 2017, 47, 2797-2810.	2.7	49
12	Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk. Translational Psychiatry, 2017, 7, e1196-e1196.	2.4	49
13	Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia. Schizophrenia Research, 2016, 174, 71-76.	1.1	47
14	Mental health services for infectious disease outbreaks including COVID-19: a rapid systematic review. Psychological Medicine, 2020, 50, 2498-2513.	2.7	44
15	Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. Pharmacogenomics Journal, 2020, 20, 192-201.	0.9	41
16	Insula Functional Connectivity in Schizophrenia: Subregions, Gradients, and Symptoms. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 399-408.	1.1	35
17	Meta-analysis reveals associations between genetic variation in the 5′ and 3′ regions of Neuregulin-1 and schizophrenia. Translational Psychiatry, 2017, 7, e1004-e1004.	2.4	32
18	Low levels of muscarinic M1 receptor–positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia. Journal of Psychiatry and Neuroscience, 2018, 43, 338-346.	1.4	30

#	Article	IF	Citations
19	Convergent evidence for mGluR5 in synaptic and neuroinflammatory pathways implicated in ASD. Neuroscience and Biobehavioral Reviews, 2015, 52, 172-177.	2.9	29
20	SELENBP1 expression in the prefrontal cortex of subjects with schizophrenia. Translational Psychiatry, 2015, 5, e615-e615.	2.4	27
21	Why academic psychiatry is endangered. Australian and New Zealand Journal of Psychiatry, 2015, 49, 9-12.	1.3	25
22	Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients. Translational Psychiatry, 2017, 7, 1280.	2.4	25
23	Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations. Translational Psychiatry, 2017, 7, e1037-e1037.	2.4	21
24	Interrogating the Evolutionary Paradox of Schizophrenia: A Novel Framework and Evidence Supporting Recent Negative Selection of Schizophrenia Risk Alleles. Frontiers in Genetics, 2019, 10, 389.	1.1	21
25	Peripheral Transcription of NRG-ErbB Pathway Genes Are Upregulated in Treatment-Resistant Schizophrenia. Frontiers in Psychiatry, 2017, 8, 225.	1.3	20
26	The schizophrenia genetics knowledgebase: a comprehensive update of findings from candidate gene studies. Translational Psychiatry, 2019, 9, 205.	2.4	19
27	Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine. International Journal of Neuropsychopharmacology, 2014, 17, 895-906.	1.0	16
28	Interaction between HIV and intravenous heroin abuse?. Journal of Neuroimmunology, 2004, 147, 13-15.	1,1	15
29	Risk and resilience brain networks in treatment-resistant schizophrenia. Schizophrenia Research, 2018, 193, 284-292.	1.1	15
30	No preliminary evidence of differences in astrocyte density within the white matter of the dorsolateral prefrontal cortex in autism. Molecular Autism, 2017, 8, 64.	2.6	13
31	The distribution of muscarinic M1 receptors in the human hippocampus. Journal of Chemical Neuroanatomy, 2016, 77, 187-192.	1.0	12
32	Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders. Translational Psychiatry, 2022, 12, 145.	2.4	12
33	Neuregulin-1 (<i>NRG1</i>) polymorphisms linked with psychosis transition are associated with enlarged lateral ventricles and white matter disruption in schizophrenia. Psychological Medicine, 2018, 48, 801-809.	2.7	10
34	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1295-1305.	1.3	10
35	Embedding a Recovery Orientation into Neuroscience Research: Involving People with a Lived Experience in Research Activity. Psychiatric Quarterly, 2016, 87, 75-88.	1.1	8
36	A survey of the mental health workforce in Guangdong: implications for policy and workforce planning. Australasian Psychiatry, 2015, 23, 675-678.	0.4	6

#	Article	IF	CITATIONS
37	Assessment of Placental Cortisol Pathway Gene Expression in Term Pregnant Women with Anxiety. Neuropsychobiology, 2019, 77, 1-7.	0.9	6
38	Response to Belgard et al Molecular Psychiatry, 2014, 19, 407-409.	4.1	4
39	The contemporary AIDS database and brain bank-lessons from the past. Journal of Neural Transmission Supplementum, 1993, 39, 77-85.	0.5	4
40	Mental health system development in Asia: Does Australia have a role?. Australian and New Zealand Journal of Psychiatry, 2016, 50, 834-841.	1.3	3
41	O1.6. INCREASED COMPLEMENT FACTORS C3 AND C4 IN SCHIZOPHRENIA AND THE EARLY STAGES OF PSYCHOSIS: IMPLICATIONS FOR CLINICAL SYMPTOMATOLOGY AND CORTICAL THICKNESS. Schizophrenia Bulletin, 2018, 44, S74-S74.	2.3	2
42	Response to Robinson et al Molecular Psychiatry, 2015, 20, 794-794.	4.1	0
43	F15. DIFFERENTIAL EXPRESSION PATTERNS OF EPIDERMAL GROWTH FACTOR (EGF) AND IMMUNE SYSTEM MARKERS IN DORSOLATERAL PREFRONTAL (BA46) AND ORBITOFRONTAL (BA11) CORTICES IN SCHIZOPHRENIA AND MOOD DISORDER. Schizophrenia Bulletin, 2018, 44, S224-S224.	2.3	0
44	F192. SYSTEMATIC META-ANALYSIS IDENTIFIES FIVE NOVEL ASSOCIATION LOCI FOR SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S295-S296.	2.3	0
45	T157. FRONTOSTRIATAL CONNECTIVITY IN TREATMENT-RESISTANT SCHIZOPHRENIA: RELATIONSHIP TO POSITIVE SYMPTOMS AND COGNITIVE FLEXIBILITY. Schizophrenia Bulletin, 2018, 44, S176-S177.	2.3	0
46	4.3 HIPPOCAMPAL SUBFIELDS AND VISUOSPATIAL ASSOCIATIVE MEMORY ACROSS STAGES OF SCHIZOPHRENIA-SPECTRUM DISORDER. Schizophrenia Bulletin, 2019, 45, S92-S92.	2.3	0
47	F95. DISRUPTION IN HIPPOCAMPAL-PREFRONTAL WHITE MATTER PATHWAYS AND MEMORY PERFORMANCE ACROSS STAGES OF SCHIZOPHRENIA-SPECTRUM DISORDER. Schizophrenia Bulletin, 2019, 45, S290-S290.	2.3	0
48	S187. EXPLORING NEURODEVELOPMENTAL AND FAMILIAL ORIGINS OF NEUROLOGICAL SOFT SIGNS IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S109-S109.	2.3	0